AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
